 | • レポートコード：QFJ1-5077 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、アルツハイマー病＆パーキンソン病の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アルツハイマー病、パーキンソン病）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・アルツハイマー病＆パーキンソン病の市場動向 ・企業の競争状況、市場シェア ・アルツハイマー病＆パーキンソン病の種類別市場規模と予測2016-2027（アルツハイマー病、パーキンソン病） ・アルツハイマー病＆パーキンソン病の用途別市場規模と予測2016-2027（病院、診療所、その他） ・アルツハイマー病＆パーキンソン病の北米市場規模2016-2027（アメリカ、カナダ） ・アルツハイマー病＆パーキンソン病の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・アルツハイマー病＆パーキンソン病のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アルツハイマー病＆パーキンソン病の中南米市場規模2016-2027（メキシコ、ブラジル） ・アルツハイマー病＆パーキンソン病の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Hoffmann-La Roche、Novartis、Pfizer、Merck、Eli Lilly、Orion Pharma、UCB、AstraZeneca、Biogen、Teva Pharmaceutical Industries、AbbVie、Vertical Pharmaceuticals、ALLERGAN、ACADIA Pharmaceuticals、Impax Laboratories、GE healthcare、VTV Therapeutics） ・結論 |
Alzheimer is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. Parkinson is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.
Market Analysis and Insights: Global Alzheimers and Parkinsons Diseases Market
The global Alzheimers and Parkinsons Diseases market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Alzheimers and Parkinsons Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Alzheimers and Parkinsons Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Alzheimers and Parkinsons Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Alzheimers and Parkinsons Diseases market.
Global Alzheimers and Parkinsons Diseases Scope and Market Size
Alzheimers and Parkinsons Diseases market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimers and Parkinsons Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Alzheimers
Parkinsons
Segment by Application
Hospital
Clinic
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Hoffmann-La Roche
Novartis
Pfizer
Merck
Eli Lilly
Orion Pharma
UCB
AstraZeneca
Biogen
Teva Pharmaceutical Industries
AbbVie
Vertical Pharmaceuticals
ALLERGAN
ACADIA Pharmaceuticals
Impax Laboratories
GE healthcare
VTV Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alzheimers and Parkinsons Diseases Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alzheimers
1.2.3 Parkinsons
1.3 Market by Application
1.3.1 Global Alzheimers and Parkinsons Diseases Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alzheimers and Parkinsons Diseases Market Perspective (2016-2027)
2.2 Alzheimers and Parkinsons Diseases Growth Trends by Regions
2.2.1 Alzheimers and Parkinsons Diseases Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Alzheimers and Parkinsons Diseases Historic Market Share by Regions (2016-2021)
2.2.3 Alzheimers and Parkinsons Diseases Forecasted Market Size by Regions (2022-2027)
2.3 Alzheimers and Parkinsons Diseases Industry Dynamic
2.3.1 Alzheimers and Parkinsons Diseases Market Trends
2.3.2 Alzheimers and Parkinsons Diseases Market Drivers
2.3.3 Alzheimers and Parkinsons Diseases Market Challenges
2.3.4 Alzheimers and Parkinsons Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alzheimers and Parkinsons Diseases Players by Revenue
3.1.1 Global Top Alzheimers and Parkinsons Diseases Players by Revenue (2016-2021)
3.1.2 Global Alzheimers and Parkinsons Diseases Revenue Market Share by Players (2016-2021)
3.2 Global Alzheimers and Parkinsons Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Alzheimers and Parkinsons Diseases Revenue
3.4 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio
3.4.1 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alzheimers and Parkinsons Diseases Revenue in 2020
3.5 Alzheimers and Parkinsons Diseases Key Players Head office and Area Served
3.6 Key Players Alzheimers and Parkinsons Diseases Product Solution and Service
3.7 Date of Enter into Alzheimers and Parkinsons Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alzheimers and Parkinsons Diseases Breakdown Data by Type
4.1 Global Alzheimers and Parkinsons Diseases Historic Market Size by Type (2016-2021)
4.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Type (2022-2027)
5 Alzheimers and Parkinsons Diseases Breakdown Data by Application
5.1 Global Alzheimers and Parkinsons Diseases Historic Market Size by Application (2016-2021)
5.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Alzheimers and Parkinsons Diseases Market Size (2016-2027)
6.2 North America Alzheimers and Parkinsons Diseases Market Size by Type
6.2.1 North America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021)
6.2.2 North America Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027)
6.2.3 North America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2027)
6.3 North America Alzheimers and Parkinsons Diseases Market Size by Application
6.3.1 North America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021)
6.3.2 North America Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027)
6.3.3 North America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2027)
6.4 North America Alzheimers and Parkinsons Diseases Market Size by Country
6.4.1 North America Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021)
6.4.2 North America Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Alzheimers and Parkinsons Diseases Market Size (2016-2027)
7.2 Europe Alzheimers and Parkinsons Diseases Market Size by Type
7.2.1 Europe Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021)
7.2.2 Europe Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027)
7.2.3 Europe Alzheimers and Parkinsons Diseases Market Size by Type (2016-2027)
7.3 Europe Alzheimers and Parkinsons Diseases Market Size by Application
7.3.1 Europe Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021)
7.3.2 Europe Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027)
7.3.3 Europe Alzheimers and Parkinsons Diseases Market Size by Application (2016-2027)
7.4 Europe Alzheimers and Parkinsons Diseases Market Size by Country
7.4.1 Europe Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021)
7.4.2 Europe Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size (2016-2027)
8.2 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type
8.2.1 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type (2016-2027)
8.3 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application
8.3.1 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application (2016-2027)
8.4 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region
8.4.1 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Alzheimers and Parkinsons Diseases Market Size (2016-2027)
9.2 Latin America Alzheimers and Parkinsons Diseases Market Size by Type
9.2.1 Latin America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021)
9.2.2 Latin America Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027)
9.2.3 Latin America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2027)
9.3 Latin America Alzheimers and Parkinsons Diseases Market Size by Application
9.3.1 Latin America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021)
9.3.2 Latin America Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027)
9.3.3 Latin America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2027)
9.4 Latin America Alzheimers and Parkinsons Diseases Market Size by Country
9.4.1 Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021)
9.4.2 Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size (2016-2027)
10.2 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type
10.2.1 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type (2016-2027)
10.3 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application
10.3.1 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application (2016-2027)
10.4 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country
10.4.1 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Hoffmann-La Roche
11.1.1 Hoffmann-La Roche Company Details
11.1.2 Hoffmann-La Roche Business Overview
11.1.3 Hoffmann-La Roche Alzheimers and Parkinsons Diseases Introduction
11.1.4 Hoffmann-La Roche Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.1.5 Hoffmann-La Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Alzheimers and Parkinsons Diseases Introduction
11.2.4 Novartis Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Alzheimers and Parkinsons Diseases Introduction
11.3.4 Pfizer Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Alzheimers and Parkinsons Diseases Introduction
11.4.4 Merck Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Alzheimers and Parkinsons Diseases Introduction
11.5.4 Eli Lilly Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.5.5 Eli Lilly Recent Development
11.6 Orion Pharma
11.6.1 Orion Pharma Company Details
11.6.2 Orion Pharma Business Overview
11.6.3 Orion Pharma Alzheimers and Parkinsons Diseases Introduction
11.6.4 Orion Pharma Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.6.5 Orion Pharma Recent Development
11.7 UCB
11.7.1 UCB Company Details
11.7.2 UCB Business Overview
11.7.3 UCB Alzheimers and Parkinsons Diseases Introduction
11.7.4 UCB Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.7.5 UCB Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Alzheimers and Parkinsons Diseases Introduction
11.8.4 AstraZeneca Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 Biogen
11.9.1 Biogen Company Details
11.9.2 Biogen Business Overview
11.9.3 Biogen Alzheimers and Parkinsons Diseases Introduction
11.9.4 Biogen Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.9.5 Biogen Recent Development
11.10 Teva Pharmaceutical Industries
11.10.1 Teva Pharmaceutical Industries Company Details
11.10.2 Teva Pharmaceutical Industries Business Overview
11.10.3 Teva Pharmaceutical Industries Alzheimers and Parkinsons Diseases Introduction
11.10.4 Teva Pharmaceutical Industries Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.10.5 Teva Pharmaceutical Industries Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Alzheimers and Parkinsons Diseases Introduction
11.11.4 AbbVie Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.11.5 AbbVie Recent Development
11.12 Vertical Pharmaceuticals
11.12.1 Vertical Pharmaceuticals Company Details
11.12.2 Vertical Pharmaceuticals Business Overview
11.12.3 Vertical Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction
11.12.4 Vertical Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.12.5 Vertical Pharmaceuticals Recent Development
11.13 ALLERGAN
11.13.1 ALLERGAN Company Details
11.13.2 ALLERGAN Business Overview
11.13.3 ALLERGAN Alzheimers and Parkinsons Diseases Introduction
11.13.4 ALLERGAN Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.13.5 ALLERGAN Recent Development
11.14 ACADIA Pharmaceuticals
11.14.1 ACADIA Pharmaceuticals Company Details
11.14.2 ACADIA Pharmaceuticals Business Overview
11.14.3 ACADIA Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction
11.14.4 ACADIA Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.14.5 ACADIA Pharmaceuticals Recent Development
11.15 Impax Laboratories
11.15.1 Impax Laboratories Company Details
11.15.2 Impax Laboratories Business Overview
11.15.3 Impax Laboratories Alzheimers and Parkinsons Diseases Introduction
11.15.4 Impax Laboratories Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.15.5 Impax Laboratories Recent Development
11.16 GE healthcare
11.16.1 GE healthcare Company Details
11.16.2 GE healthcare Business Overview
11.16.3 GE healthcare Alzheimers and Parkinsons Diseases Introduction
11.16.4 GE healthcare Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.16.5 GE healthcare Recent Development
11.17 VTV Therapeutics
11.17.1 VTV Therapeutics Company Details
11.17.2 VTV Therapeutics Business Overview
11.17.3 VTV Therapeutics Alzheimers and Parkinsons Diseases Introduction
11.17.4 VTV Therapeutics Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021)
11.17.5 VTV Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Alzheimers and Parkinsons Diseases Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alzheimers
Table 3. Key Players of Parkinsons
Table 4. Global Alzheimers and Parkinsons Diseases Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Alzheimers and Parkinsons Diseases Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Alzheimers and Parkinsons Diseases Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Alzheimers and Parkinsons Diseases Market Share by Regions (2016-2021)
Table 8. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Alzheimers and Parkinsons Diseases Market Share by Regions (2022-2027)
Table 10. Alzheimers and Parkinsons Diseases Market Trends
Table 11. Alzheimers and Parkinsons Diseases Market Drivers
Table 12. Alzheimers and Parkinsons Diseases Market Challenges
Table 13. Alzheimers and Parkinsons Diseases Market Restraints
Table 14. Global Alzheimers and Parkinsons Diseases Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Alzheimers and Parkinsons Diseases Market Share by Players (2016-2021)
Table 16. Global Top Alzheimers and Parkinsons Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimers and Parkinsons Diseases as of 2020)
Table 17. Ranking of Global Top Alzheimers and Parkinsons Diseases Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Alzheimers and Parkinsons Diseases Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Alzheimers and Parkinsons Diseases Product Solution and Service
Table 21. Date of Enter into Alzheimers and Parkinsons Diseases Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2016-2021)
Table 25. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Alzheimers and Parkinsons Diseases Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Application (2016-2021)
Table 29. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 61. Hoffmann-La Roche Company Details
Table 62. Hoffmann-La Roche Business Overview
Table 63. Hoffmann-La Roche Alzheimers and Parkinsons Diseases Product
Table 64. Hoffmann-La Roche Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 65. Hoffmann-La Roche Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Alzheimers and Parkinsons Diseases Product
Table 69. Novartis Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer Alzheimers and Parkinsons Diseases Product
Table 74. Pfizer Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 75. Pfizer Recent Development
Table 76. Merck Company Details
Table 77. Merck Business Overview
Table 78. Merck Alzheimers and Parkinsons Diseases Product
Table 79. Merck Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Alzheimers and Parkinsons Diseases Product
Table 84. Eli Lilly Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. Orion Pharma Company Details
Table 87. Orion Pharma Business Overview
Table 88. Orion Pharma Alzheimers and Parkinsons Diseases Product
Table 89. Orion Pharma Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 90. Orion Pharma Recent Development
Table 91. UCB Company Details
Table 92. UCB Business Overview
Table 93. UCB Alzheimers and Parkinsons Diseases Product
Table 94. UCB Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 95. UCB Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 99. AstraZeneca Recent Development
Table 100. Biogen Company Details
Table 101. Biogen Business Overview
Table 102. Biogen Alzheimers and Parkinsons Diseases Product
Table 103. Biogen Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 104. Biogen Recent Development
Table 105. Teva Pharmaceutical Industries Company Details
Table 106. Teva Pharmaceutical Industries Business Overview
Table 107. Teva Pharmaceutical Industries Alzheimers and Parkinsons Diseases Product
Table 108. Teva Pharmaceutical Industries Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 109. Teva Pharmaceutical Industries Recent Development
Table 110. AbbVie Company Details
Table 111. AbbVie Business Overview
Table 112. AbbVie Alzheimers and Parkinsons Diseases Product
Table 113. AbbVie Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 114. AbbVie Recent Development
Table 115. Vertical Pharmaceuticals Company Details
Table 116. Vertical Pharmaceuticals Business Overview
Table 117. Vertical Pharmaceuticals Alzheimers and Parkinsons Diseases Product
Table 118. Vertical Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 119. Vertical Pharmaceuticals Recent Development
Table 120. ALLERGAN Company Details
Table 121. ALLERGAN Business Overview
Table 122. ALLERGAN Alzheimers and Parkinsons Diseases Product
Table 123. ALLERGAN Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 124. ALLERGAN Recent Development
Table 125. ACADIA Pharmaceuticals Company Details
Table 126. ACADIA Pharmaceuticals Business Overview
Table 127. ACADIA Pharmaceuticals Alzheimers and Parkinsons Diseases Product
Table 128. ACADIA Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 129. ACADIA Pharmaceuticals Recent Development
Table 130. Impax Laboratories Company Details
Table 131. Impax Laboratories Business Overview
Table 132. Impax Laboratories Alzheimers and Parkinsons Diseases Product
Table 133. Impax Laboratories Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 134. Impax Laboratories Recent Development
Table 135. GE healthcare Company Details
Table 136. GE healthcare Business Overview
Table 137. GE healthcare Alzheimers and Parkinsons Diseases Product
Table 138. GE healthcare Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 139. GE healthcare Recent Development
Table 140. VTV Therapeutics Company Details
Table 141. VTV Therapeutics Business Overview
Table 142. VTV Therapeutics Alzheimers and Parkinsons Diseases Product
Table 143. VTV Therapeutics Revenue in Alzheimers and Parkinsons Diseases Business (2016-2021) & (US$ Million)
Table 144. VTV Therapeutics Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alzheimers and Parkinsons Diseases Market Share by Type: 2020 VS 2027
Figure 2. Alzheimers Features
Figure 3. Parkinsons Features
Figure 4. Global Alzheimers and Parkinsons Diseases Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Other Case Studies
Figure 8. Alzheimers and Parkinsons Diseases Report Years Considered
Figure 9. Global Alzheimers and Parkinsons Diseases Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Alzheimers and Parkinsons Diseases Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Alzheimers and Parkinsons Diseases Market Share by Regions: 2020 VS 2027
Figure 12. Global Alzheimers and Parkinsons Diseases Market Share by Regions (2022-2027)
Figure 13. Global Alzheimers and Parkinsons Diseases Market Share by Players in 2020
Figure 14. Global Top Alzheimers and Parkinsons Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimers and Parkinsons Diseases as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Alzheimers and Parkinsons Diseases Revenue in 2020
Figure 16. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2016-2021)
Figure 17. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2022-2027)
Figure 18. North America Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Alzheimers and Parkinsons Diseases Market Share by Type (2016-2027)
Figure 20. North America Alzheimers and Parkinsons Diseases Market Share by Application (2016-2027)
Figure 21. North America Alzheimers and Parkinsons Diseases Market Share by Country (2016-2027)
Figure 22. United States Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Alzheimers and Parkinsons Diseases Market Share by Type (2016-2027)
Figure 26. Europe Alzheimers and Parkinsons Diseases Market Share by Application (2016-2027)
Figure 27. Europe Alzheimers and Parkinsons Diseases Market Share by Country (2016-2027)
Figure 28. Germany Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Alzheimers and Parkinsons Diseases Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Alzheimers and Parkinsons Diseases Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Alzheimers and Parkinsons Diseases Market Share by Region (2016-2027)
Figure 38. China Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Alzheimers and Parkinsons Diseases Market Share by Type (2016-2027)
Figure 46. Latin America Alzheimers and Parkinsons Diseases Market Share by Application (2016-2027)
Figure 47. Latin America Alzheimers and Parkinsons Diseases Market Share by Country (2016-2027)
Figure 48. Mexico Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Alzheimers and Parkinsons Diseases Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Alzheimers and Parkinsons Diseases Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Alzheimers and Parkinsons Diseases Market Share by Country (2016-2027)
Figure 54. Turkey Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Alzheimers and Parkinsons Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Hoffmann-La Roche Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 58. Novartis Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 59. Pfizer Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 60. Merck Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 61. Eli Lilly Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 62. Orion Pharma Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 63. UCB Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 65. Biogen Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 66. Teva Pharmaceutical Industries Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 67. AbbVie Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 68. Vertical Pharmaceuticals Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 69. ALLERGAN Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 70. ACADIA Pharmaceuticals Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 71. Impax Laboratories Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 72. GE healthcare Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 73. VTV Therapeutics Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
世界の寄生虫病治療市場規模・現状・予測（2021年-2027年） Parasitic diseases include amebiasis, trichomoniasis, trypanosomiasis, giardiasis, African sleeping sickness, leishmaniasis, and malaria. Market Analysis and Insights: Global Parasitic Diseases Therapeutic Market The global Parasitic Diseases Therapeutic market size is projected to reach US$ XX mill…- 世界の子宮疾患治療薬市場規模・現状・予測（2021年-2027年） Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important. Market Analysis and Insights: Global Uterine Diseases …
- 世界のアルコール性肝疾患治療市場規模・現状・予測（2021年-2027年） Alcoholic liver diseases are the result of overconsumption of alcohol, which damages the liver, leading to liver cirrhosis, inflammation, and liver scarring. Market Analysis and Insights: Global Alcoholic Liver Diseases Treatment Market The global Alcoholic Liver Diseases Treatment market size is p…
- 世界のIVD感染症市場規模・現状・予測（2021年-2027年） In Vitro Diagnostics (IVDs) are medical devices and accessories used to perform tests on samples, (e.g., blood, urine and tissue that has been taken from the human body) in order to help detect infection, Diagnose a medical condition and Prevent disease. Market Analysis and Insights: Global IVD Infe…
- 世界のゴーシェ病＆ポンペ病酵素補充療法市場規模・現状・予測（2021年-2027年） Enzyme replacement therapy (ERT) involves intravenous (IV) infusions to correct the underlying enzyme deficiency that causes symptoms of Gaucher disease Market Analysis and Insights: Global Gaucher and Pompe Diseases Enzyme Replacement Therapy Market The global Gaucher and Pompe Diseases Enzyme Repl…